S Wassel1, E Tsompanidi1, E Tahmaz1, B Hörster1, R Hoerster2. 1. MVZ ADTC Mönchengladbach/Erkelenz GmbH, Ostpromenade 41, 41812, Erkelenz, Deutschland. 2. MVZ ADTC Mönchengladbach/Erkelenz GmbH, Ostpromenade 41, 41812, Erkelenz, Deutschland. r.hoerster@augencentrumerkelenz.de.
Abstract
BACKGROUND: The clinical outcome of neovascular age-related macular degeneration (nAMD) depends on constant follow-up and consistent treatment. Data about the long-term course of intensive anti-vascular endothelial growth factor (VEGF) therapy from outpatient clinics are rare. OBJECTIVE: The aim of the study was to characterize a population of nAMD patients with long-term follow-up and intensive anti-VEGF therapy. PATIENTS AND METHODS: In a supra-regional outpatient clinic, we retrospectively identified patients who had received at least 30 intravitreal anti-VEGF injections and were followed for at least 4 years. All patients received an optical coherence tomography(OCT)-controlled Pro-Re-Nata (PRN) therapy regimen according to German guidelines. RESULTS: We identified 43 patients. Visual acuity at baseline was 0.44 ± 0.24 (1.0-0.1) logMAR. At the end of the follow-up period, visual acuity was 0.63 ± 3.6 (1.3-0.1) logMAR. Patients received a mean of 36.3 ± 8.0 (30-62) injections and were followed for a mean of 6.1 ± 1.8 (4-12) years. They received 6.12 ± 1.5 (3.1-9.9) injections per year. The number of injections in treatment-year one was with 3.67 ± 1.9 (1-8) significantly lower than the mean (p < 0.0001). CONCLUSION: Despite intensive PRN therapy, visual acuity slowly decreased over time. The mean number of injections was comparable to that of prospective studies. The low number of injections in treatment-year 1 may have been due to a lack of experience with the new treatment agents. The slow decrease in visual acuity in clinical routine as opposed to clinical studies may be attributed to a delay between occurrence of disease activity and treatment.
BACKGROUND: The clinical outcome of neovascular age-related macular degeneration (nAMD) depends on constant follow-up and consistent treatment. Data about the long-term course of intensive anti-vascular endothelial growth factor (VEGF) therapy from outpatient clinics are rare. OBJECTIVE: The aim of the study was to characterize a population of nAMD patients with long-term follow-up and intensive anti-VEGF therapy. PATIENTS AND METHODS: In a supra-regional outpatient clinic, we retrospectively identified patients who had received at least 30 intravitreal anti-VEGF injections and were followed for at least 4 years. All patients received an optical coherence tomography(OCT)-controlled Pro-Re-Nata (PRN) therapy regimen according to German guidelines. RESULTS: We identified 43 patients. Visual acuity at baseline was 0.44 ± 0.24 (1.0-0.1) logMAR. At the end of the follow-up period, visual acuity was 0.63 ± 3.6 (1.3-0.1) logMAR. Patients received a mean of 36.3 ± 8.0 (30-62) injections and were followed for a mean of 6.1 ± 1.8 (4-12) years. They received 6.12 ± 1.5 (3.1-9.9) injections per year. The number of injections in treatment-year one was with 3.67 ± 1.9 (1-8) significantly lower than the mean (p < 0.0001). CONCLUSION: Despite intensive PRN therapy, visual acuity slowly decreased over time. The mean number of injections was comparable to that of prospective studies. The low number of injections in treatment-year 1 may have been due to a lack of experience with the new treatment agents. The slow decrease in visual acuity in clinical routine as opposed to clinical studies may be attributed to a delay between occurrence of disease activity and treatment.
Authors: Philipp Sebastian Muether; Manuel M Hermann; Konrad Koch; Sascha Fauser Journal: Graefes Arch Clin Exp Ophthalmol Date: 2010-09-24 Impact factor: 3.117
Authors: Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Robert Hoerster; Philipp S Muether; Manuel M Hermann; Konrad Koch; Bernd Kirchhof; Sascha Fauser Journal: Br J Ophthalmol Date: 2011-07-18 Impact factor: 4.638
Authors: Maureen G Maguire; Daniel F Martin; Gui-Shuang Ying; Glenn J Jaffe; Ebenezer Daniel; Juan E Grunwald; Cynthia A Toth; Frederick L Ferris; Stuart L Fine Journal: Ophthalmology Date: 2016-05-02 Impact factor: 12.079
Authors: Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe Journal: N Engl J Med Date: 2011-04-28 Impact factor: 91.245
Authors: Geeta A Lalwani; Philip J Rosenfeld; Anne E Fung; Sander R Dubovy; Stephen Michels; William Feuer; Janet L Davis; Harry W Flynn; Maria Esquiabro Journal: Am J Ophthalmol Date: 2009-04-18 Impact factor: 5.258
Authors: Philipp S Muether; Robert Hoerster; Manuel M Hermann; Bernd Kirchhof; Sascha Fauser Journal: Graefes Arch Clin Exp Ophthalmol Date: 2012-05-11 Impact factor: 3.117